Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
CalciMedica, a clinical-stage biopharma company, is developing potentially first-in-class small molecules to combat excessive intracellular calcium levels that drive pathological processes in inflammatory diseases and acute injury, including COVID-19.
As a government funder, the Korea Drug Development Fund (KDDF) invests in promising selected compounds by taking them through assessment and translating them into cutting-edge science for patient benefits and market opportunities.
The city of Phoenix hosts a thriving life-sciences ecosystem that fosters collaboration among industry, education, research and community partners to transform discoveries into health.
City of Phoenix Community and Economic Development Department
Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.
Enterome is using its unique Mimicry approach coupled with the power of partnering to harness the potential of the gut’s natural tolerance pathway to address allergies and autoimmune diseases.
Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.
Solarea Bio is harnessing the diversity of the edible plant microbiota to deliver medical food products that aid the dietary management of inflammatory disorders and support healthy aging.
With Exeliom Biosciences’s drug candidate, EXL01, the long-touted immune-modulation potential of a key gut bacterial species is finally reaching patients in the clinic.
Microbiotica’s platform makes it a leader in precision clinical discovery of novel microbiome-based therapeutics and biomarkers. With the platform validated at scale, and a pipeline of programs, the company is open to collaborations in both therapeutic and biomarker discovery.
Using innovative particle-engineering technology, Alveolus Bio is developing a platform that delivers live biotherapeutic products deep into the lungs for the treatment of chronic and infectious respiratory disease.
Minaris Regenerative Medicine is developing large-scale 3D cell-production processes and optimizing its culture parameters, as well as enabling in-house batch certification, to enable its partners to realize the huge potential of cell therapies.
Shape Therapeutics is developing next-generation gene-therapy technologies that harness the power of artificial intelligence and RNA editing to repair disease-causing mutations.
Asgard Therapeutics is moving cancer immunotherapy forward with an off-the-shelf direct cell reprogramming platform that turns cancer cells into immunogenic dendritic cells that induce potent anticancer immunity.
Precision BioSciences is transforming drug development for new, potentially first- and best-in-class cell and gene therapies with its proprietary ARCUS gene-editing platform, which is derived from a small, naturally occurring DNA-editing nuclease.
By coupling Twist Bioscience’s DNA-writing technology with expertise in antibody engineering, Twist Biopharma can accelerate the development of new biologics and cell therapies.
With a focus on detecting, intercepting, treating, and ultimately curing cancer, Janssen Oncology is advancing science and solutions in hematologic malignancies and solid tumors through an innovative strategic partnering approach.
